APSR2026-558

 
Late-Breaking
Submitted
Poster Presentation
 
AP14-054
P73
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1216446-46904-MET EXON FINAL POSTER_440553.pdf
Format: PDF Only
08. Lung Cancer
5

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Nicole Chui-Jiet Fong * Hospital Queen Elizabeth Respiratory Department Sabah Malaysia
Sunn-Ren Tee - Hospital Queen Elizabeth Respiratory Department Sabah Malaysia
Rong Lih Ho - Hospital Queen Elizabeth Respiratory Department Sabah Malaysia
Hema Yamini Ramarmuty - Hospital Queen Elizabeth Respiratory Department Sabah Malaysia
Kunji Kannan Sivaraman Kannan - Hospital Queen Elizabeth Respiratory Department Sabah Malaysia
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Nicole Chui-Jiet
Fong
nicole.fong8246@gmail.com
+601119561128
Under 30
Malaysia
Case Report
MET exon 14 skipping lung adenocarcinoma initially presumed metastatic but downstaged to surgical candidacy after PET-CT and EBUS
Maximum 25 words
Abstract Content
 
 
 
 
Accurate staging in lung cancer is important for the treatment intent and prognosis. Computed tomography (CT) can overestimate disease burden due to complex parenchymal abnormalities. Therefore, multimodal staging is essential to prevent misclassification of potentially curable disease. Concurrently, rare driver mutations, such as MET exon 14 skipping (3–4% of NSCLC), carry important therapeutic implications.
A 77-year-old former smoker with hypertension and chronic kidney disease stage 3b presented with a four-month history of chronic productive cough without constitutional symptoms. Tuberculosis workup was negative. CT thorax showed mosaic attenuation with peribronchovascular consolidation, traction bronchiectasis, reticulations, calcified foci in the left upper lobe, scattered ground-glass nodules involving contralateral lobes, cystic changes, and biapical pleural thickening. These findings suggested disseminated malignancy and the disease was initially considered T2N3M1a. Radial endobronchial ultrasound biopsy confirmed lung adenocarcinoma. Nonetheless, PET-CT showed a solitary FDG-avid left upper lobe mass (3.4 × 2.5 × 3.4 cm, SUVmax 12.69) without mediastinal or distant metastasis. Absence of nodal involvement was confirmed by linear EBUS, resulting in downstaging to T2N0M0 and eligibility for curative surgical resection. Next-generation sequencing identified a MET exon 14 skipping mutation, with no EGFR, KRAS, BRAF, ALK or ROS1 alterations.
This case reveals two important points. First, PET-CT together with EBUS is essential for avoiding radiological overstaging and for converting presumed metastatic disease to resectable cancer with curative intent. Second, identification of MET exon 14 skipping defines a rare, actionable subtype. Present management post downstaging is surgical resection with consideration of perioperative or adjuvant chemo-immunotherapy depending on pathological staging and risk factors. MET inhibitors are not standard in the perioperative setting but being available as a targeted option if recurrence occurs contributes to a personalized treatment approach and may improve long-term outcomes.
 
 
Yes
No
 
JPG or JPEG or PNG format ONLY
MET exon 14 skipping mutation, lung adenocarcinoma, PET-CT
maximum 3 keywords and no abbreviations, separated by commas
The authors would like to express their sincere appreciation to all department staff for their involvement in the management of this patient.
287